secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019682
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports Q1 2023 net loss of $19.3M; cash $315.4M; Phase 1 MAD data for DT-216 expected in Q3 2023
--------------------------------------------------------------------------------

- Net loss of $19.3M for Q1 2023; R&D expenses $15.7M, G&A expenses $5.9M.
- Cash, equivalents and marketable securities $315.4M, expected to fund operations through 2025.
- Initial Phase 1 multiple-ascending dose trial data for DT-216 in Friedreich ataxia expected Q3 2023.
- IND submission for DT-168 eye drop for FECD on track for H2 2023; preclinical data presented at ARVO 2023.
- IND submission for DM1 GeneTAC program on track for H2 2024; development candidate selection underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/dsgn-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer